(Q50710138)

18 March 2018

title

The costs of vascular dementia: a comparison with Alzheimer's disease. (English)

1 reference

18 March 2018

1 reference

Howard Fillit

1

1 reference

18 March 2018

Jerrold Hill

series ordinal

2

1 reference

18 March 2018

publication date

1 November 2002

1 reference

18 March 2018

Journal of the Neurological Sciences

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

18 March 2018

volume

203-204

1 reference

18 March 2018

page(s)

35-39

1 reference

18 March 2018

Epidemiology of dementia and Alzheimer's disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Epidemiology of multi-infarct dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Treatment options: the latest evidence with galantamine (Reminyl).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

The US economic and social costs of Alzheimer's disease revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Cognitive function and the costs of Alzheimer disease. An exploratory study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

The economic burden of Alzheimer's disease care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Alzheimer's disease care: costs and potential savings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Cost of Alzheimer's disease and related dementia in managed-medicare.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

How much do persons with Alzheimer's disease cost Medicare?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Impact of the type and severity of dementia on hospitalization and survival of the elderly. The SAGE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Societal costs of vascular cognitive impairment in older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Chronic care costs in managed care.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

An economic evaluation of donepezil in the treatment of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900257-5

10.1016/S0022-510X(02)00257-5

7 January 2021

Identifiers

DOI

1 reference

18 March 2018

1 reference

18 March 2018